S-1 in the treatment of advanced and recurrent gastric cancer: current state and future prospects


S-1 (TS-1®) is a novel oral anticancer drug. Because of the excellent results of phase II studies, we continued to prescribe S-1 for advanced or recurrent gastric cancer after we participated in the phase I and II studies. Twenty-nine patients with advanced or recurrent gastric cancer were treated with S-1. Clinicopathological features, survival, and… (More)
DOI: 10.1007/s10120-003-0228-5


7 Figures and Tables

Slides referencing similar topics